Wu Chia-Yung, Rupp Levi J, Roybal Kole T, Lim Wendell A
Dept. of Cellular & Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94158, United States.
Dept. of Cellular & Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94158, United States; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA 94158, United States.
Curr Opin Immunol. 2015 Aug;35:123-30. doi: 10.1016/j.coi.2015.06.015. Epub 2015 Jul 25.
There is rapidly growing interest in learning how to engineer immune cells, such as T lymphocytes, because of the potential of these engineered cells to be used for therapeutic applications such as the recognition and killing of cancer cells. At the same time, our knowhow and capability to logically engineer cellular behavior is growing rapidly with the development of synthetic biology. Here we describe how synthetic biology approaches are being used to rationally alter the behavior of T cells to optimize them for therapeutic functions. We also describe future developments that will be important in order to construct safe and precise T cell therapeutics.
由于工程化免疫细胞（如T淋巴细胞）在识别和杀伤癌细胞等治疗应用方面的潜力，人们对学习如何构建这类细胞的兴趣正迅速增长。与此同时，随着合成生物学的发展，我们在逻辑上设计细胞行为的技术和能力也在迅速提高。在此，我们描述了如何利用合成生物学方法合理改变T细胞的行为，以优化其治疗功能。我们还阐述了构建安全、精准的T细胞疗法未来所需的重要进展。
